Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the PK properties, tolerability, and safety of lorcaserin HCL (BELVIQ) in obese adolescent subjects between the ages of 12 to 17 years old

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Arena Pharmaceuticals; Eisai Inc.

Criteria

Inclusion Criteria:

1. Adolescent subjects aged 12 to 17 years, inclusive at screening

2. a. Eligible female subjects who are sexually active will be:

• non-pregnant

• non-lactating

• agree to continue to use an accepted method of birth control for at least 1 month after study medication administration

3. BMI ≥ 95th percentile for age and gender, but ≤ 44 kg/m21

4. Considered to be in stable health in the opinion of the Investigator.

5. Parent or guardian who can sign written informed consent and subject willing to sign assent

Exclusion Criteria:

1. Clinically significant new illness in the 1 month before screening and any time prior to randomization

2. Significant renal or hepatic disease

3. Secondary (chromosomal, endocrine, or metabolic) causes of obesity

4. Use of medications other than hormonal contraceptives and acetaminophen

5. Use of drugs with serotonergic activity within 1 month before screening

6. Recent treatment with over-the-counter weight loss products or appetite suppressants, or within 3 months of screening and any time prior to randomization with a prescription weight loss drug or lipid dissolving injections or ongoing psychotherapy for weight loss outside of this trial

7. Recent history of alcohol, tobacco, or recreational drug/solvent use

8. Any history of major depression, anxiety, bipolar disorder, schizophrenia, or Axis II psychiatric disease requiring treatment with prescription medication within six months prior to screening